3,6-双邻(alpha-d-呋喃鼠李糖)-d-呋喃鼠李糖 | 121123-33-9

• 物质功能分类: 生物化工 - 糖类化合物 - 寡糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,6-双邻(alpha-d-呋喃鼠李糖)-d-呋喃鼠李糖
• 中文别名: Α3,Α6-甘露三糖
• 英文名称: 3,6-Di-O-(alpha-D-mannopyranosyl)-D-mannopyrannose
• 英文别名: 2-(hydroxymethyl)-6-[[3,5,6-trihydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol
• CAS: 121123-33-9
• 化学式: C₁₈H₃₂O₁₆
• 分子量: 504.4
• InChiKey: KJZMZIMBDAXZCX-UHFFFAOYSA-N

物化性质

• 熔点：
  140-145°C
• 沸点：
  879.4±65.0 °C(Predicted)
• 密度：
  1.80±0.1 g/cm3(Predicted)
• 溶解度：
  可微溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  -6.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  269
• 氢给体数：
  11
• 氢受体数：
  16

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  29400090

文献信息

• TARGETING LIPIDS
  申请人：Arbutus Biopharma Corporation

  公开号：EP3156077A1

  公开（公告）日：2017-04-19

  The present invention provides targeting lipids of structure (Cl) L100 - linker - L101, where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or -CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

  本发明提供了结构为（Cl）L100-连接体-L101的靶向脂质，其中L100为脂质、亲脂质、烷基、烯基或炔基，L101为配体或-CH2CH2(OCH2CH2)pO(CH2)qCH2-配体，p为1-1000，q为1-20。此外，本发明还提供了向细胞输送治疗剂的组合物和方法。其中特别包括新型脂质和核酸-脂质颗粒，它们能有效地封装核酸，并在体内将封装的核酸有效地递送到细胞中。
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3546579A1

  公开（公告）日：2019-10-02

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚化合物与 N-乙酰半乳糖胺共轭。
• COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3564374A1

  公开（公告）日：2019-11-06

  The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.

  本公开内容一般涉及用于研究、诊断和/或治疗的化学修饰寡核苷酸。在某些实施方案中，本公开内容描述了用于调节靶核酸的化合物和方法。在某些实施方案中，本公开内容描述了用于调节载脂蛋白 C-III 表达的化合物和方法。
• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3690049A1

  公开（公告）日：2020-08-05

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

  本文提供的是具有针对载脂蛋白 C-III（ApoCIII）的共轭基团的低聚化合物。在某些实施方案中，载脂蛋白 CIII 靶向低聚物化合物与 N-乙酰半乳糖胺共轭。本文还公开了用于减少载脂蛋白CIII以治疗、预防或改善与载脂蛋白CIII有关的疾病、失调或状况的靶向载脂蛋白CIII的共轭低聚物化合物。与载脂蛋白 CIII 有关的某些疾病、失调或病症包括炎症、心血管和/或代谢性疾病、失调或病症。本文公开的共轭低聚物化合物可用于治疗有需要的个体的此类疾病、失调或病症。
• GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3845547A1

  公开（公告）日：2021-07-07

  Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

  本文提供了减少动物体内 ANGPTL3 mRNA 和蛋白质表达的方法、化合物和组合物。本文还提供了用于降低动物体内血脂和/或葡萄糖的方法、化合物和组合物。这些方法、化合物和组合物有助于治疗、预防、延缓或改善有需要的个体的心血管疾病和/或代谢疾病中的一种或多种，或其症状。